AGTX-301

AGTX-301 (identified in some contexts by the transcription error or placeholder name **n-moricab**) is a preclinical-stage monoclonal antibody being developed by **Agentix Australia**, a subsidiary of Agentix Corp. The drug is designed as a peripherally restricted antagonist of the **cannabinoid receptor 1 (CB1)** for the treatment of metabolic disorders, primarily **type 2 diabetes**. Unlike earlier small-molecule CB1 antagonists such as rimonabant, which were associated with significant central nervous system (CNS) side effects like anxiety and depression, AGTX-301 is a large-molecule biologic intended to remain outside the blood-brain barrier. By selectively blocking CB1 receptors in peripheral tissues—including the liver, pancreas, and adipose tissue—the antibody aims to improve insulin sensitivity, reduce hepatic fat, and enhance glucose metabolism without inducing psychiatric adverse effects. The name 'n-moricab' likely stems from a transcription error of the descriptor 'Novel mAb' or a misreading of the candidate code in pipeline documentation.

Other names

n-moricabAgentix CB1 monoclonal antibody